What are the initial dosing guidelines for Abilify Maintena (aripiprazole) in adults with schizophrenia or bipolar I disorder?

Early Dosing Guidelines for Abilify Maintena

For Abilify Maintena (aripiprazole long-acting injectable), initiate with 400 mg intramuscularly as both the starting and maintenance dose, with mandatory continuation of oral aripiprazole 10-20 mg daily (or another oral antipsychotic) for 14 consecutive days after the first injection to ensure therapeutic plasma concentrations are achieved. 1

Initial Dosing Protocol

Starting Dose

• 400 mg intramuscularly is the recommended starting dose for both schizophrenia and bipolar I disorder maintenance treatment 1
• This same 400 mg dose serves as the maintenance dose for ongoing treatment 2
• The injection should be administered in the deltoid or gluteal muscle 1

Critical Oral Overlap Period

• Continue oral aripiprazole (10-20 mg/day based on prior stabilization dose) or the patient's current oral antipsychotic for 14 days after the first Abilify Maintena injection 1, 2
• This overlap is essential because pharmacokinetic data show that while median aripiprazole plasma concentrations reach therapeutic levels within 7 days, interpatient variability necessitates the full 14-day overlap to ensure all patients achieve therapeutic concentrations 2
• The therapeutic window for aripiprazole is 94.0-534.0 ng/mL, and the 14-day overlap ensures concentrations of 93-112 ng/mL are achieved by week 4 2

Pre-Initiation Stabilization Strategy

Switching from Other Antipsychotics

• If the patient is not already on oral aripiprazole, cross-titrate from their current oral antipsychotic to oral aripiprazole over >1 to 4 weeks before initiating Abilify Maintena 2
• This gradual cross-titration (versus ≤1 week) significantly reduces discontinuation rates due to adverse events (2.7% vs 10.4%) 2
• Target oral aripiprazole dose during stabilization: 10-30 mg/day 2

For Patients Already on Oral Aripiprazole

• Patients previously stabilized on oral aripiprazole 10-30 mg/day can directly initiate Abilify Maintena 400 mg 2
• Continue their stabilized oral dose (10-15 mg/day) for the mandatory 14-day overlap period 2

Maintenance Dosing Schedule

Standard Regimen

• Administer 400 mg intramuscularly once monthly after the initial dose 1
• Clinical studies demonstrated that 90.1% (1296/1439) of patients required no dose change from the 400 mg starting dose 2
• Discontinuation rates due to lack of efficacy were low (2.3%-10.0% across studies) 2

Alternative 2-Month Formulation

• A newer formulation (Ari2M 960 mg) can be administered every 2 months as an alternative to monthly dosing 3, 4
• This formulation uses a ready-to-use prefilled syringe and must be administered in the gluteal muscle 3
• The 960 mg every 2 months dose is pharmacokinetically equivalent to 400 mg monthly 3, 4

Dose Adjustments for Drug Interactions

Reduce the Abilify Maintena dose by half (to 200 mg monthly) when patients are:

• Known CYP2D6 poor metabolizers 1
• Taking concomitant strong CYP3A4 inhibitors 1
• Taking concomitant strong CYP2D6 inhibitors 1

Increase the dose when strong CYP3A4 inducers are co-administered 1

Clinical Considerations

Efficacy of 400 mg Starting Dose

• The 400 mg dose was efficacious and well-tolerated across multiple clinical trials 2
• Efficacy and safety were comparable regardless of whether patients were previously stabilized on oral aripiprazole 10 mg or 30 mg daily 2

Common Pitfall to Avoid

• Do not skip or shorten the 14-day oral overlap period, as this is the most critical error in initiation that can lead to subtherapeutic concentrations and symptom breakthrough 2
• The pharmacokinetic variability between patients makes the full 14-day overlap necessary even though median concentrations reach therapeutic levels by day 7 2